emerging trends in diabetes
Download
Skip this Video
Download Presentation
Emerging Trends in Diabetes

Loading in 2 Seconds...

play fullscreen
1 / 38

Emerging Trends in Diabetes - PowerPoint PPT Presentation


  • 136 Views
  • Uploaded on

Emerging Trends in Diabetes. Robert Lash, MD Professor of Internal Medicine University of Michigan Health System. 1994. 1995. 1996. 1997. 1998. 1999. 2000. 2001. 2002. 2003. 2004. 2005. 2006. 2007. 2008. 2009. 2010. What’s new in diabetes?.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Emerging Trends in Diabetes' - bailey


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
emerging trends in diabetes

Emerging Trends in Diabetes

Robert Lash, MD

Professor of Internal Medicine

University of Michigan Health System

what s new in diabetes
What’s new in diabetes?
  • Recognizing that diabetes has a variety of ‘causes’, with treatments to match
  • New thinking about endpoints: Is lowering glucose enough?
  • A new medicine that does the wrong thing for the right reason
  • Finally, some real progress on the ‘artificial pancreas’
slide20

Sulfonylureas (and insulin)

Metformin

Type 2diabetes

Thiazolidinediones

lnsulin receptor pathway

Glucose

C

2009

ProteinLounge.com

INSULIN

PIP2

PIP3

Lipid Raft

InsulinReceptor

GLUT4

GLUT4Translocation

lnsulin Receptor Pathway

P

P

SHC

GRB2

PIP2

PI3K

SOS

P

Flotillin

PIP3

IRS1

P

P

Crk

Ras

Nck

P

c-CbI

GTP

CAP

Fyn

ReceptorInternalization

P

Rab4

GRB10

P

P

GLUT4Vesicle

Raf

SHC

IRS1/2

P

P

H+

P

Insulin Degradation& ReceptorDephosphorylation

APS

PPtase1

H+

c-CbI

P

PDK

ATP Citrate lyase

P

PKC

P

P

Rac

P

MEKs

P

AktPKB

EBS

Translation

Insulin

Translation

Anti-apoptosis

Fatty AcidSynthesis

GeneExpression

TRE

Gene Expression

mTOR

Insulin

EAI

ERKs

EAI

GlycogenSynthase

BAD

GSK3

p70S6K

eIF4EBP

FKHRL1

EEF2K

P

BAD

JNK

S6

eIF2B

14-3-3

EEF2

eIF4

Elk

c-Jun

c-Fos

slide22

Sulfonylureas (and insulin)

Metformin

Type 2diabetes

Thiazolidinediones

GLP-I analogs & DPP IV inhibitors

slide24

GLP-1release

Gosh, I’m full!

DPP-4 inhibitor

DPP-4 enzyme

Increased

insulin secretion

X

Decreased glucagon secretion

Inactive metabolites

GLP-1Mechanisms of Action

Reduced hepatic glucose output

slide25

Sulfonylureas (and insulin)

Metformin

Type 2diabetes

Thiazolidinediones

GLP-I analogs & DPP IV inhibitors

what s new in diabetes1
What’s new in diabetes?
  • Recognizing that diabetes has a variety of ‘causes’, with treatments to match
  • New thinking about endpoints: Is lowering glucose enough?
  • A new medicine that does the wrong thing for the right reason
  • Finally, some real progress on the ‘artificial pancreas’
slide27

“Diabetes is a remarkable affliction, not very frequent among men… The course is the common one, namely, the kidneys and the bladder; for the patients never stop making water, but the flow is incessant, as if from the opening of aqueducts.

“Moreover, life is disgusting and painful; thirst, unquenchable; excessive drinking, which, however, is disproportionate to the large quantity of urine, for more urine is passed; and one cannot stop them either from drinking or making water.”

cefalu wt leiter la et al lancet 2013 382 941 50

Efficacy and safety of canagliflozin versus glimepiride inpatients with type 2 diabetes inadequately controlled withmetformin (CANTATA-SU): 52 week results from arandomised, double-blind, phase 3 non-inferiority trial

Cefalu WT, Leiter LA, et. al.Lancet 2013; 382: 941–50

slide31

Sulfonylureas (and insulin)

Metformin

Type 2Diabetes

Thiazolidinediones

GLP-I analogs &DPP IV inhibitors

SGLT2 inhibitors

what s new in diabetes2
What’s new in diabetes?
  • Recognizing that diabetes has a variety of ‘causes’, with treatments to match
  • New thinking about endpoints: Is lowering glucose enough?
  • A new medicine that does the wrong thing for the right reason
  • Finally, some tangible progress on the ‘artificial pancreas’
threshold based insulin pump interruption for reduction of hypoglycemia

Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia

Bergenstal RM, Klonoff DC, et. al.N Engl J Med 2013;369:224-32.

slide36

Frequency and severity of hypoglycemia

‘Duration’ of hypoglycemic events

Bergenstal RM, Klonoff DC, et. al.N Engl J Med 2013;369:224-32.

what s new in diabetes3
What’s new in diabetes?
  • Recognizing that diabetes has a variety of ‘causes’, with treatments to match
  • New thinking about endpoints: Is lowering glucose enough?
  • A new medicine that does the wrong thing for the right reason
  • Finally, some tangible progress on the ‘artificial pancreas’
ad